Published in Ann Intern Med on December 07, 2004
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol (2011) 4.26
IgG4-related sclerosing disease. World J Gastroenterol (2008) 3.84
Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol (2006) 3.40
Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol (2007) 2.60
Hyper-IgG4 disease: report and characterisation of a new disease. BMC Med (2006) 2.08
IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab (2011) 1.58
Are Classification Criteria for IgG4-RD Now Possible? The Concept of IgG4-Related Disease and Proposal of Comprehensive Diagnostic Criteria in Japan. Int J Rheumatol (2012) 1.56
IgG4-related chronic rhinosinusitis: a new clinical entity of nasal disease. Acta Otolaryngol (2010) 1.04
A novel immunoglobulin-immunoglobulin interaction in autoimmunity. PLoS One (2008) 0.96
Review of the diagnosis, classification and management of autoimmune pancreatitis. World J Gastrointest Pathophysiol (2014) 0.95
Japanese consensus guidelines for management of autoimmune pancreatitis: II. Extrapancreatic lesions, differential diagnosis. J Gastroenterol (2010) 0.94
Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. Am J Pathol (2016) 0.82
Histologically confirmed isolated IgG4-related hypophysitis: two case reports in young women. Endocrinol Diabetes Metab Case Rep (2014) 0.81
Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 II. Extrapancreatic lesions, differential diagnosis. J Gastroenterol (2014) 0.79
Thickened Pituitary Stalk Associated with a Mass in the Sphenoidal Sinus: An Alarm to Suspect Hypophysitis by Immunoglobulin G4? Int Arch Otorhinolaryngol (2015) 0.77
Clinical course of IgG4-related hypophysitis presenting with focal seizure and relapsing lymphocytic hypophysitis. BMC Endocr Disord (2015) 0.77
Is primary sclerosing cholangitis different from sclerosing cholangitis with autoimmune pancreatitis? J Gastroenterol (2007) 0.76
IgG4-Related Hypophysitis: Case Report and Literature Review. Cureus (2016) 0.75
IgG4-Related Disease Presenting as a Solitary Neck Mass. J Radiol Case Rep (2015) 0.75
Rituximab was used to treat recurrent IgG4-related hypophysitis with ophthalmopathy as the initial presentation: A case report and literature review. Medicine (Baltimore) (2017) 0.75
Immunoglobulin G4 (IgG4)-Related Hypophysitis. Endocr Pathol (2017) 0.75
Clinicopathologic features of orbital immunoglobulin G4-related disease (IgG4-RD): a case series and literature review. Graefes Arch Clin Exp Ophthalmol (2015) 0.75
Hypophysitis: Evaluation and Management. Clin Diabetes Endocrinol (2016) 0.75
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer (2005) 1.39
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood (2002) 1.21
Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol (2007) 1.13
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res (2008) 1.01
Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol (2007) 0.98
Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. J Immunol Methods (2007) 0.90
Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol (2008) 0.90
Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide. Clin Immunol (2010) 0.87
Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases. Immunol Lett (2008) 0.78